Shots:

• The EUA is based on P-III study evaluating regdanvimab vs PBO in adults with COVID-19 who do not require supplemental oxygen & are at high risk of progression to severe COVID-19
• The results demonstrated a 72% reduction in risk of COVID-19 related hospitalization or death in high-risk patients & 70% for all patients- shortened time to clinical recovery (4.7 vs 4.9 days). The therapy also showed a safety- tolerability- antiviral effect & efficacy profile
• Additionally- in vitro & in vivo studies demonstrated the potency of regdanvimab against multiple variants of concern including Alpha- Beta- Gamma & Delta variants. The therapy also showed strong neutralizing capability against Lambda variant

  | Ref: Celltrion | Image: Celltrion